Driving growth in a family-owned pharma company requires a balance of progress and preservation, writes Merz Therapeutics CEO ...

Sometimes the key to making a breakthrough in research, in any field, is to look at the problem differently than anybody has ...

Fear of change is a key limiting factor that is slowing the adoption and value of AI across life sciences. It doesn't have to ...

Cuts to federal research funding at universities and research organizations are pushing academic scientists into life sciences entrepreneurship. Experts at Sidley offer tips for the transition.

BIO was as busy as ever in Boston this year. With more to come soon, here are a few initial thoughts on three events I attended.

The IRS has changed what must be reported upon filing a research and development (R&D) tax credit claim, and the impact is especially significant for the life sciences industry. The tax form used to ...

Smart money will find good ideas, and if you follow the money in biotech these days, that means looking to China. From January to mid-May 2025, Chinese biotechnology companies had announced licensing ...

The biopharma industry is rapidly evolving. As such, biopharma companies are facing a variety of operational challenges stemming from a high volume of siloed data coupled with regulatory scrutiny that ...

For more than two decades, the EU has pledged numerous initiatives aimed at creating regulatory environments to foster both innovation and investment in the EU’s biotech sector, a sector which broadly ...

By Stephen Beckman Stephen Beckman A revolution is coming in the U.S. generics marketplace, one that players in the space ignore at their peril. This revolution has the potential to transform savvy ...

Patient safety is the top priority for regulators. While the industry and the public advocate for alternatives to animal testing, regulators require strong evidence that alternatives are equally safe ...